pre-ipo
Stage
1
Investors
About
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, including treatments for hepatitis C virus and other serious viral diseases. The company has an exclusive ex-US partnership with Roche and is publicly traded on NASDAQ under the ticker AVIR.
Explore Atea Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.